We treated 17 patients who had moderate to severe Alzheimer's disease with oral tetrahydroaminoacridine (THA), a centrally active anticholinesterase, in a three-phase study. In the nonblinded first phase of the study, significant improvement occurred in subjects who received the drug, as compared with their pretreatment status, on the global assessment (P = 0.001), the Orientation Test (P = 0.001), and the more sophisticated Names Learning Test (P = 0.001). During the second phase, the subjects served as their own controls in a double-blind, placebo-controlled, cross-over study in which the order of administration of the drug and placebo was randomly assigned. Among the 14 subjects completing Phase II, THA treatment produced significantly better results than placebo on the global assessment (P = 0.003), the Orientation Test (P = 0.004), the Alzheimer's Deficit Scale (P = 0.003), and the Names Learning Test (P = 0.001). Twelve subjects have entered Phase III, which involves long-term administration of oral THA. The average duration of treatment in these subjects at present is 12.6 months; symptomatic improvements have occurred, and no serious side effects attributable to THA have been observed. These encouraging initial results suggest that THA may be at least temporarily useful in the long-term palliative treatment of patients with Alzheimer's disease. We stress that further observations will be required before a clear assessment of the role of this agent can be made.
This article has been cited by other articles:
Groner, E., Ashani, Y., Schorer-Apelbaum, D., Sterling, J., Herzig, Y., Weinstock, M.
(2007). The Kinetics of Inhibition of Human Acetylcholinesterase and Butyrylcholinesterase by Two Series of Novel Carbamates. Mol. Pharmacol.
71: 1610-1617
[Abstract][Full Text]
Lin, P. I., Martin, E. R., Bronson, P. G., Browning-Large, C., Small, G. W., Schmechel, D. E., Welsh-Bohmer, K. A., Haines, J. L., Gilbert, J. R., Pericak-Vance, M. A.
(2006). Exploring the association of glyceraldehyde-3-phosphate dehydrogenase gene and Alzheimer disease.. Neurology
67: 64-68
[Abstract][Full Text]
Becker, R. E.
(2006). Treating Alzheimer's disease: Do clinical trial methods produce unnecessary practitioner dilemmas?. AM J ALZHEIMERS DIS OTHER DEMEN
21: 81-84
[Abstract]
Sung, J.-H., Yu, K.-H., Park, J.-S., Tsuruo, T., Kim, D.-D., Shim, C.-K., Chung, S.-J.
(2005). SATURABLE DISTRIBUTION OF TACRINE INTO THE STRIATAL EXTRACELLULAR FLUID OF THE RAT: EVIDENCE OF INVOLVEMENT OF MULTIPLE ORGANIC CATION TRANSPORTERS IN THE TRANSPORT. Drug Metab. Dispos.
33: 440-448
[Abstract][Full Text]
Mesulam, M.
(2004). The Cholinergic Lesion of Alzheimer's Disease: Pivotal Factor or Side Show?. Learn. Mem.
11: 43-49
[Abstract][Full Text]
Whitehouse, P. J.
(2003). Lessons and Responses in Alzheimer Disease Research. JAMA
290: 115-115
[Full Text]
Rosner, G. L., Stadler, W., Ratain, M. J.
(2002). Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents. JCO
20: 4478-4484
[Abstract][Full Text]
Bekkelund, S. I., Kujala, I., Rosenvinge, B.
(2001). Unrecognized Dementia in Elderly Patients Admitted to Hospital with Psychiatric Symptoms. J Geriatr Psychiatry Neurol
14: 7-10
[Abstract]
Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., Workman, P.
(1999). Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?. JNCI J Natl Cancer Inst
91: 1281-1287
[Full Text]
Richards, S. S., Hendrie, H. C.
(1999). Diagnosis, Management, and Treatment of Alzheimer Disease: A Guide for the Internist. Arch Intern Med
159: 789-798
[Abstract][Full Text]
Flicker, L.
(1999). Acetylcholinesterase inhibitors for Alzheimer's disease. BMJ
318: 615-616
[Full Text]
Ye, J. W., Cai, J. X., Wang, L. M., Tang, X. C.
(1999). Improving Effects of Huperzine A on Spatial Working Memory in Aged Monkeys and Young Adult Monkeys with Experimental Cognitive Impairment. J. Pharmacol. Exp. Ther.
288: 814-819
[Abstract][Full Text]
Felician, O., Sandson, T. A.
(1999). The Neurobiology and Pharmacotherapy of Alzheimer's Disease. J. Neuropsychiatry Clin. Neurosi.
11: 19-31
[Abstract][Full Text]
Katsube, N., Sunaga, K., Aishita, H., Chuang, D.-M., Ishitani, R.
(1999). ONO-1603, a Potential Antidementia Drug, Delays Age-Induced Apoptosis and Suppresses Overexpression of Glyceraldehyde-3-Phosphate Dehydrogenase in Cultured Central Nervous System Neurons. J. Pharmacol. Exp. Ther.
288: 6-13
[Abstract][Full Text]
Papka, M., Rubio, A., Schiffer, R. B.
(1998). A Review of Lewy Body Disease, an Emerging Concept of Cortical Dementia. J. Neuropsychiatry Clin. Neurosi.
10: 267-279
[Abstract][Full Text]
Ishitani, R., Tanaka, M., Sunaga, K., Katsube, N., Chuang, D.-M.
(1998). Nuclear Localization of Overexpressed Glyceraldehyde-3-Phosphate Dehydrogenase in Cultured Cerebellar Neurons Undergoing Apoptosis. Mol. Pharmacol.
53: 701-707
[Abstract][Full Text]
Tsukada, H., Kakiuchi, T., Ando, I., Ouchi, Y.
(1997). . J. Pharmacol. Exp. Ther.
281: 1408-1414
[Abstract]
Ishitani, R., Sunaga, K., Tanaka, M., Aishita, H., Chuang, D.-M.
(1997). Overexpression of Glyceraldehyde-3-Phosphate Dehydrogenase Is Involved in Low K+-Induced Apoptosis but Not Necrosis of Cultured Cerebellar Granule Cells. Mol. Pharmacol.
51: 542-550
[Abstract][Full Text]
Lintern, M., Smith, M., Ferry, C.
(1997). Effect of repeated treatment with pyridostigmine on acetylcholinesterase in mouse muscles. Hum Exp Toxicol
16: 158-165
[Abstract]
Hirai, K., Kato, K., Nakayama, T., Hayako, H., Ishihara, Y., Goto, G., Miyamoto, M.
(1997). Neurochemical Effects of 3-[1-(Phenylmethyl)-4-Piperidinyl]-1-(2,3,4,5-Tetrahydro-1H-1-Benzazepin-8-yl)-1-Propanone Fumarate (TAK-147), a Novel Acetylcholinesterase Inhibitor, in Rats. J. Pharmacol. Exp. Ther.
280: 1261-1269
[Abstract][Full Text]
Smith, C. P., Bores, G. M., Petko, W., Li, M., Selk, D. E., Rush, D. K., Camacho, F., Winslow, J. T., Fishkin, R., Cunningham, D. M., Brooks, K. M., Roehr, J., Hartman, H. B., Davis, L., Vargas, H. M.
(1997). Pharmacological Activity and Safety Profile of P10358, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer's Disease. J. Pharmacol. Exp. Ther.
280: 710-720
[Abstract][Full Text]
Lintern, M. C, Smith, M. E, Ferry, C B.
(1997). Effects of pyridostingmine on acetylcholinesterase in different muscles of the mouse. Hum Exp Toxicol
16: 18-24
[Abstract]
Kirby, M., Lawlor, B. A.
(1995). Biologic Markers and Neurochemical Correlates of Agitation and Psychosis in Dementia. J Geriatr Psychiatry Neurol
8: S2-S7
[Abstract]
Allen, N.H.P., Burns, A.
(1995). The treatment of Alzheimer's disease. J Psychopharmacol
9: 43-56
Byrne, E, Arie, T
(1994). Tetrahydroaminoacridine and Alzheimer's disease. BMJ
308: 868-869
[Full Text]
Maltby, N, Broe, G A, Creasey, H, Jorm, A F, Christensen, H, Brooks, W S
(1994). Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. BMJ
308: 879-883
[Abstract][Full Text]
Perryman, K. M., Fitten, L. J.
(1991). Quantitative EEG During a Double-Blind Trial of THA and Lecithin in Patients with Alzheimer's Disease. J Geriatr Psychiatry Neurol
4: 127-133
[Abstract]
McGuire, B. E
(1990). Review article : Psychopharmacological treatments for memory impairment. Clin Rehabil
4: 235-244
Sahgal, A., Keith, A.B., Lloyd, S.
(1990). Effects of nicotine, oxotremorine and 9-amino 1,2,3,4- tetrahydroacridine (tacrine) on matching and non matching to position in rats: no evidence for mnemonic enhancement. J Psychopharmacol
4: 210-218
[Abstract]
Jenike, M. A.
(1988). Alzheimer's Disease--What the Practicing Clinician Needs to Know. J Geriatr Psychiatry Neurol
1: 37-46
